How Will The Empagliflozin, Dapagliflozin And Canagliflozin Market Expand At A CAGR Of 2.4% Through 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Will The Empagliflozin, Dapagliflozin And Canagliflozin Market Valuation Change Between Now And 2029?
The market size for empagliflozin, dapagliflozin and canagliflozin has consistently risen in the past few years. The market projected to expand from $9.64 billion in 2024 to $9.84 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 2.1%. The anterior growth can be ascribed to factors such as the escalated occurrence of type 2 diabetes globally, heightened awareness of the advantages of SGLT2 inhibitors, an increase in the aging population, a rise in obesity cases, and a growing emphasis on personalized medicine.
The market for empagliflozin, dapagliflozin and canagliflozin is projected to witness consistent expansion in the upcoming years. It’s estimated to reach a value of $10.82 billion by 2029, with a compound annual growth rate (CAGR) of 2.4%. The growth during the forecast period is expected to be driven by the rise in demand for oral diabetes drugs, increase in investment in diabetes research and medication creation, growing healthcare spending, enhanced identification and awareness of pre-diabetes conditions, and heightened emphasis on combination treatments. Key trends during this forecast period will be technological breakthroughs, combination treatments, telehealth, analysis of health data, and securing patient data.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
What Growth-Enabling Forces Are Impacting The Empagliflozin, Dapagliflozin And Canagliflozin Market?
The escalated rise of diabetes is anticipated to fuel the expansion of the empagliflozin, dapagliflozin, and canagliflozin market. Diabetes is a continuous health concern characterized by elevated blood sugar levels, resulting from inadequate insulin production or inefficient use of insulin by the body. The rise in diabetes cases can be linked to elements like inactive lifestyles, unhealthy eating patterns, genetic factors, urbanization, and the growth of older population. These are further aggravated by insufficient healthcare access and increasing global obesity numbers. Empagliflozin, dapagliflozin, and canagliflozin play a crucial role in handling diabetes as they reduce blood sugar levels by restraining sodium-glucose co-transporter-2 (SGLT2) in the kidneys, which leads to the expulsion of glucose through urine. As per the NHS, UK’s government-run health organization, there was a noticeable increase in diabetes instances among people under the age of 40, escalating from 173,166 in 2022 to 216,440 in 2023. This significant uptick underscores a worryingly increasing trend in this age segment, showing swift intensification in diabetes rates amongst younger demographics. Hence, with the rise in diabetes cases, the empagliflozin, dapagliflozin, and canagliflozin market is witnessing significant growth.
What Are The Main Segment Classifications In The Empagliflozin, Dapagliflozin And Canagliflozin Market?
The empagliflozin, dapagliflozin and canagliflozinmarket covered in this report is segmented –
1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin
2) By Application: Application I; Application II; Application III; Application IV
3) By Channel: Hospital; Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg; 25 Mg; 50 Mg
2) Dapagliflozin: 5 Mg; 10 Mg
3) Canagliflozin: 100 Mg; 300 Mg
How Are Industry Trends Steering The Expansion Of The Empagliflozin, Dapagliflozin And Canagliflozin Market?
Leading companies in the empagliflozin, dapagliflozin, and canagliflozin markets are prioritizing the production of innovative products such as treatments for pediatric type-2 diabetes. This strategy allows them to cater to a broader demographic and extend their influence in the diabetes care sector. Pediatric Type-2 diabetes treatment primarily involves managing blood sugar levels via lifestyle modifications, prescribed medicines, and occasionally insulin therapy specially created for children and teenagers. For example, AstraZeneca, a pharmaceutical company based in the UK, revealed in June 2024 that their product Farxiga (dapagliflozin) has received the approval of the US Food and Drug Administration (FDA) to enhance glycemic control in pediatric patients aged ten years and above with type 2 diabetes. This approval was given based on the positive outcomes from the T2NOW Phase III clinical trial, one of the most comprehensive pediatric type-2 diabetes trials thus far, indicating that Farxiga substantially reduced HbA1c levels when compared to a placebo. Farxiga’s safety profile in this particular patient group was found to be in line with what was observed in adults with type-2 diabetes. This approval marks a significant milestone, given that oral treatment alternatives for pediatric type-2 diabetes have been scarce, thereby highlighting AstraZeneca’s dedication to providing innovative treatment options across cardiovascular, renal, and metabolic diseases.
Which Firms Are Driving Innovation Within The Empagliflozin, Dapagliflozin And Canagliflozin Market?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Empagliflozin, Dapagliflozin And Canagliflozin Market?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp
Browse Through More Reports Similar to the Global Empagliflozin, Dapagliflozin And Canagliflozin Market 2025, By The Business Research Company
Biofuel Enzymes Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biofuel-enzymes-global-market-report
Blood Brain Barrier Technologies Global Market Report 2025
Carcinoembryonic Antigen Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/carcinoembryonic-antigen-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
